CareDx (CDNA) said Friday it has released a proposed draft Local Coverage Determination on molecular testing for solid organ allograft rejection.
There is no change in current coverage and the draft policy is open for comment through Aug. 31, the company said. The proposal also introduces a bundled payment model for surveillance testing.
The company said it is reviewing the draft policy and plans to provide additional information at its earnings call on Aug. 6.
Shares of CareDx were up more than 3% in recent trading.
Price: 12.22, Change: +0.41, Percent Change: +3.47
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.